AURKA and non-small cell lung carcinoma: To determine the degree to which SMARCA4 loss correlated with sensitivity to inhibition of AURKA, we measured the sensitivity to VX-680 across a panel of NSCLC and HBEC lines known to be either SMARCA4-wild-type or mutant (Supplementary Data 3) and therefore express or lack the SMARCA4 protein, respectively (Fig. 4b).